DOD Biotech PCL (BKK:DOD) Cyclically Adjusted Revenue per Share: ฿2.05 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BKK:DOD DOD Biotech PCL BKK:DOD
73 GF Score
Price ฿1.13
GF Value ฿1.67
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is DOD Biotech PCL Cyclically Adjusted Revenue per Share?

DOD Biotech PCL BKK:DOD -0.88% 73 Cyclically Adjusted Revenue per Share is ฿2.05 as of Mar. 2026. GuruFocus rates BKK:DOD with a GF Score™ of 73/100 and a GF Value™ of ฿1.67 (Possible Value Trap). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

DOD Biotech PCL's adjusted revenue per share for the three months ended in Mar. 2026 was ฿0.266. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ฿2.05 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-02), DOD Biotech PCL's current stock price is ฿1.13. DOD Biotech PCL's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was ฿2.05. DOD Biotech PCL's Cyclically Adjusted PS Ratio of today is 0.55.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of DOD Biotech PCL was 0.99. The lowest was 0.57. And the median was 0.80.


DOD Biotech PCL  (BKK:DOD) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

DOD Biotech PCL's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1.13/2.05
=0.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of DOD Biotech PCL was 0.99. The lowest was 0.57. And the median was 0.80.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


DOD Biotech PCL Cyclically Adjusted Revenue per Share Related Terms


DOD Biotech PCL Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for DOD Biotech PCL's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DOD Biotech PCL Cyclically Adjusted Revenue per Share Chart

DOD Biotech PCL Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 2.04

DOD Biotech PCL Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 2.04 2.05

BKK:DOD vs KHC, GIS: Cyclically Adjusted Revenue per Share Comparison

For the Packaged Foods subindustry, DOD Biotech PCL's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DOD Biotech PCL Cyclically Adjusted PS Ratio vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, DOD Biotech PCL's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where DOD Biotech PCL's Cyclically Adjusted PS Ratio falls into.


BKK:DOD
73GF Score
DOD Biotech PCL BKK:DOD
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DOD Biotech PCL Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, DOD Biotech PCL's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.266/330.2130*330.2130
=0.266

Current CPI (Mar. 2026) = 330.2130.

DOD Biotech PCL Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201512 0.000 236.525 0.000
201609 0.171 241.428 0.234
201612 0.223 241.432 0.305
201703 0.235 243.801 0.318
201706 0.289 244.955 0.390
201709 0.188 246.819 0.252
201712 0.249 246.524 0.334
201803 0.713 249.554 0.943
201806 0.730 251.989 0.957
201809 0.382 252.439 0.500
201812 0.148 251.233 0.195
201903 0.292 254.202 0.379
201906 0.309 256.143 0.398
201909 0.529 256.759 0.680
201912 0.790 256.974 1.015
202003 0.831 258.115 1.063
202006 0.548 257.797 0.702
202009 0.706 260.280 0.896
202012 0.927 260.474 1.175
202103 0.865 264.877 1.078
202106 0.603 271.696 0.733
202109 0.448 274.310 0.539
202112 0.554 278.802 0.656
202203 0.391 287.504 0.449
202206 0.326 296.311 0.363
202209 0.400 296.808 0.445
202212 0.192 296.797 0.214
202303 0.286 301.836 0.313
202306 0.409 305.109 0.443
202309 0.419 307.789 0.450
202312 0.406 306.746 0.437
202403 0.376 312.332 0.398
202406 0.341 314.175 0.358
202409 0.382 315.301 0.400
202412 0.333 315.605 0.348
202503 0.380 319.799 0.392
202506 0.335 322.561 0.343
202509 0.322 324.800 0.327
202512 0.315 324.054 0.321
202603 0.266 330.213 0.266

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ฿2.05 mean?
DOD Biotech PCL (BKK:DOD) has a Cyclically Adjusted Revenue per Share of ฿2.05 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on DOD Biotech PCL and its competitors.
Is DOD Biotech PCL's Cyclically Adjusted Revenue per Share too high?
DOD Biotech PCL's current Cyclically Adjusted Revenue per Share is ฿2.05. Overall, DOD Biotech PCL has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does DOD Biotech PCL's Cyclically Adjusted Revenue per Share compare to KHC and GIS?
DOD Biotech PCL's Cyclically Adjusted Revenue per Share of ฿2.05 can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Consumer Packaged Goods company?
A good Cyclically Adjusted Revenue per Share depends on the Consumer Packaged Goods industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on DOD Biotech PCL and its competitors. DOD Biotech PCL's current Cyclically Adjusted Revenue per Share is ฿2.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DOD Biotech PCL stock overvalued right now?
Based on GuruFocus' analysis, DOD Biotech PCL (BKK:DOD) is currently considered Possible Value Trap. The stock's GF Value™ is ฿1.67, compared to a current price of ฿1.13 — trading 32.3% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ฿2.05. DOD Biotech PCL's overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For DOD Biotech PCL (BKK:DOD), the current Cyclically Adjusted Revenue per Share is ฿2.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DOD Biotech PCL (BKK:DOD) Overvalued in 2026?

Based on GuruFocus' analysis, DOD Biotech PCL stock appears to be undervalued. The current stock price of ฿1.13 is trading 32.3% below its estimated GF Value™ of ฿1.67. GuruFocus considers DOD Biotech PCL to be Possible Value Trap.

Key valuation signals for BKK:DOD:

  • Cyclically Adjusted Revenue per Share: ฿2.05
  • GF Value™: ฿1.67 vs. price of ฿1.13 (32.3% below fair value)
  • GF Score™: 73/100 with 5 warning signs

No single metric tells the full story. See the BKK:DOD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


DOD Biotech PCL Business Description

Address No. 111, Moo 2, Tumbol Taa jeen, Amphor Muengsamutsakhon, Samut Sakhon, THA, 74000
DOD Biotech PCL is principally engaged in the manufacture and distribution of food supplements and health drinks of all kinds. The group is principally engaged in the supplement business. Its operations are carried on only in Thailand. Its products include: Capsule; Gel; Jelly; Powder for making drinks; Concentrated water extract (Shot Drink); Softgel; Tablet; Probiotics; Gummies; and Direct-to-Mouth Packaging.
73GF Score

Get the complete analysis for BKK:DOD

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

฿1.13
Price
฿1.67
GF Value